Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity

Journal of Cardiovascular Pharmacology
Chaim YosefyReuven J Viskoper

Abstract

Type II diabetes is often associated with high blood pressure, elevated sympathetic activity, and high plasma insulin levels. Hypoglycemic agents may negatively interfere with blood pressure control, sympathetic activity, and plasma insulin level; therefore the choice of treatment in type II diabetes may be crucial. We aimed to compare the effects of two hypoglycemic drugs on blood glucose, blood pressure, sympathetic activity, and insulin levels in type II diabetic and hypertensive patients. Forty-eight (24M, 24F) type II diabetic, hypertensive, and hyperlipidemic subjects were enrolled and treated for 4 weeks with an ACE inhibitor (Cilazapril) and a statin (Simvastatin). They were then randomized into two groups to receive a thiazolidinedione (Rosiglitazone; ROS) or a sulfonylurea (Glibenclamide; GLB) for 8 weeks. Blood biochemistry, blood pressure, plasma insulin, endothelial function, and sympathetic skin activity were measured before and after treatment. A significant drop in systolic and diastolic blood pressure by 6.1 +/- 4.1 mm Hg and 4.2 +/- 1.9 mm Hg respectively; a reduction in plasma insulin concentration by 4.3 +/- 1.9 mU/L and a decline in skin sympathetic activity were observed in the group receiving ROS. The GLB...Continue Reading

References

Jun 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·L NilssonA Hamsten
Jan 12, 2000·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·H NakayamaS Horiuchi
Jun 8, 2000·Annals of the New York Academy of Sciences·L Landsberg
Sep 27, 2000·Journal of Diabetes and Its Complications·S VallejoL Rodríguez-Mañas
Nov 15, 2000·Metabolism: Clinical and Experimental·P E Jennings
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force

❮ Previous
Next ❯

Citations

Aug 10, 2007·Current Hypertension Reports·Thomas D Giles, Gary E Sander
Oct 17, 2009·American Journal of Therapeutics·Zafar H Israili
Jan 18, 2008·Nephrology·Cheuk-Chun Szeto, Philip Kam-Tao Li
Jan 18, 2008·Nephrology·Priscilla Kincaid-SmithJoseph Proietto
Jun 17, 2006·Diabetes, Obesity & Metabolism·Kathleen L Wyne
Mar 13, 2008·Diabetes, Obesity & Metabolism·R E Buckingham, A Hanna
Nov 27, 2007·International Journal of Clinical Practice·R CubbonM T Kearney
Feb 6, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Marcia Venegas-PontMichael J Ryan
Oct 8, 2011·Circulation Research·Asif K MustafaSolomon H Snyder
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Minori NakamotoShuichi Takishita
Apr 2, 2011·Clinical Journal of the American Society of Nephrology : CJASN·John M LachinUNKNOWN ADOPT Study Group
May 25, 2011·Expert Opinion on Drug Safety·Devindra SehraShiv Tej Sehra
Sep 7, 2007·Kidney International·Y MiyazakiR A DeFronzo
Sep 11, 2007·Journal of Diabetes and Its Complications·Aaron S Kelly, Alan J Bank
Jan 8, 2009·Journal of Clinical Pharmacy and Therapeutics·G DerosaA F G Cicero
Aug 8, 2007·Journal of the Cardiometabolic Syndrome·Gurushankar GovindarajanJames R Sowers
Jul 10, 2007·The Journal of Clinical Hypertension·Beatriz de RivasArturo Fernández-Cruz
Jan 13, 2006·The Journal of Clinical Hypertension·Rehan Qayyum, Jurga Adomaityte
Aug 14, 2012·Clinical Endocrinology·Andrew Lansdown, D Aled Rees
Oct 2, 2015·Indian Journal of Endocrinology and Metabolism·Sanjay KalraUditha Bulughapitiya
Sep 7, 2016·Pharmacology & Therapeutics·Ilia GoltsmanZaid Abassi
Aug 31, 2016·Journal of Diabetes Investigation·Kyeong Seon ParkHye Seung Jung
Nov 10, 2006·Journal of the Renin-angiotensin-aldosterone System : JRAAS·M Cecilia LansangNorman K Hollenberg
Mar 18, 2006·Circulation Research·Indu G PoornimaRichard P Shannon
Sep 27, 2005·Diabetes/metabolism Research and Reviews·Rehan Qayyum, Peter Schulman
Dec 7, 2005·Journal of Hypertension·Risto J Kaaja, Maritta K Pöyhönen-Alho
Jul 26, 2006·Blood Pressure·Pantelis A Sarafidis, Peter M Nilsson
May 28, 2019·The Journal of Clinical Endocrinology and Metabolism·Andrew J LansdownD Aled Rees
Oct 19, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Daad H AkbarOmayma A Khorshid
Jul 22, 2005·Drugs·Keri Wellington
Jul 3, 2021·Journal of Clinical Medicine·Angelo CignarelliFrancesco Giorgino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.